CRISPR-Cas9 RNA-DNA complex. Structure of Cas9 endonuclease (yellow-orange) complexed with a guide RNA (blue), a target DNA (pink) and a non-target DNA (green). The revolutionary CRISPR-Cas gene editing technology has unlocked unprecedented possibilities in genome engineering, gene therapy, and cell…
Vernal is excited to announce its new partnership with REPROCELL, furthering our mission to democratize access to mRNA, a life-changing technology, around the world. REPROCELL is a trusted leader in iPSC reprograming technologies and GMP iPSC manufacturing based in Japan. Together with REPROCELL, we…
Find our latest article on Businesswire here: Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing Click the orange “Contact Us” button in the top right hand corner to find out more!
Every success has an origin story. Check out this new VT Digger article on how CEO Christian Cobaugh, Ph.D. founded Vernal Biosciences, and what makes Vernal uniquely situated to meet mRNA process development and manufacturing needs.
Vernal has successfully demonstrated its ability to manufacture high quality mRNA using CGMP-compliant platform. We now offer the first integrated platform for CGMP production of MCB, pDNA, mRNA, and LNP at our GMP facility. Contact us today to reserve your GMP…
After a successful extension of its Series A funding, Vernal Biosciences was featured in an Endpoints News article by Tyler Patchen. Find out how we are using these funds to widen our offerings and support the mRNA community, then click…
By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There…
We cannot believe it has been 2 years. Happy Birthday Vernal Biosciences! See how Vernal has grown since 2021 and expanded its capabilities for mRNA, LNP, and GMP!
Poster Abstract: Based on the clinical and commercial success of SARS-CoV-2 mRNA vaccines, interest in using lipid nanoparticle-formulated mRNA (LNP-mRNA) as a next generation, rapidly deployable vaccine platform has accelerated in the form of preclinical research and clinical trials. To…
The development of mRNA vaccines has been ongoing since the late 80s, but it wasn’t until the COVID-19 pandemic that this technology became widely recognized. Instead of using an antigen to trigger the body’s immune system to create a new…
Vernal’s mission has always been to democratize access to mRNA. One of the ways we are achieving this is expanding our capabilities in mRNA process and development so that we can provide GMP for clinical use cases. Take a look…
Download the Poster – Complete the Form Below